For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Formats:
Features:
Epidermal Growth Factor Receptor (EGFR, Her1, ErbB1) is a 134 kDa cell surface receptor apart of a four member subfamily of receptor tyrosine kinases (erbB1, erbB2, erbB3, and erbB4). EGFR binds to a family of proteins called the epidermal growth factors, which upon association induces dimerization of the receptor and initiates signal transduction for the promotion of cell survival and growth. Mutations that cause EGFR overexpression have been linked with many different types of cancer such as lung cancer or gastrointestinal tract cancers. Measuring the EGFR levels is vital for the detection of these types of cancers and is also an important target for therapeutic intervention. The AlphaLISA kit presented here has been designed for the detection of EGFR in cell culture media and serum.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Assay Target | EGFR |
---|---|
Assay Target Class | Protein |
Automation Compatible | Yes |
Detection Method | Alpha |
Experimental Type | In vitro |
Product Brand Name | AlphaLISA |
Shipping Condition | Blue Ice |
Therapeutic Area | Cancer |
Unit Size | 100 assay points |
A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.
In this application note you will learn: